ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

Two Groups Form to Mark Cancer Act’s 25th Anniversary

May 31, 1996

Race And Cancer: “It Would Be Wrong To Design Studies Based On Assumptions That Races Are Biologically Different,” Klausner Says

June 19, 1998

Survey supports removal of cancer care cuts from Medicare bills.

September 26, 2003

Rauscher “Identifies” Four More Comprehensive Centers

June 21, 1974

Survivors Urge Congress To Include Oral Drug Coverage In Medicare Legislation

October 11, 2002

MSK Withdraws Form Breast Cancer Nutrition Study Over Chemotherapy Issue; Program Still “Going Well”

June 21, 1985